Eptifibatide:

Eptifibatide, also known as Integrilin, is a medication used to reduce the risk of cardiac ischemic events such as myocardial infarctions in patients with unstable angina or non-ST-segment elevation acute coronary syndromes. It is produced by the eptifibatide manufacturers and eptifibatide suppliers Millennium Pharmaceuticals and Schering-Plough, of which Schering-Plough was a co-promoter. Currently, it can be found for both sale and wholesale on the global marketplace by distributors at an assortment of prices, largely driven by the generic nature of the product. With the pharmaceutical products patent having expired in 2014 and an additional patent revision being expired in 2015. Eptifibatide was discovered by a team led by Robert M. Scarborough and David Phillips working for the company COR Therapeutics, which was subsequently acquired by Millennium Pharmaceuticals in 2001. Manufacturing of eptifibatide is initiated through harvesting the venom of the southeastern pygmy rattlesnake (Sistrurus miliarius barbourin). This produces a compound belonging to the class of arginin-glycin-aspartat-mimetics, which function through reversibly binding to platelets conferring the antiplatelet effects.

Method of action of eptifibatide:

Eptifibatide is an anticoagulant which both selectively and reversibly binds to the platelet glycoprotein IIb/IIIa receptor. This prevents the binding of fibrinogen, von Willebrand factor, and other adhesive ligands needed for proper platelet mediated coagulation. As this inhibition of coagulation occurs due to eptifibatide competitively blocking necessary receptors, its effectiveness is dependent on both concentration and dose. This drug functions through the Eptifibatide Action Pathway and has a half-life of approximately 2.5 hours in humans.

Form and dosage of eptifibatide:

Eptifibatide can be found for sale by manufacturers and wholesale distributors in forms including solutions for injection, prefilled injection, and lyophilized powder for solution. With the exact form, packaging, and cost differing dependent on the specific list. Eptifibatide is normally administered in combination with aspirin and unfractionated heparin for the prevention of early myocardial infarction in patients with unstable angina or non-ST-segment-elevation myocardial infarction. Where recommended dosages are an initial injection of 180 micrograms/kg followed by 2 micrograms/kg/minute for up to a maximum of 96 hours. Use of eptifibatide should only be done under the guidance of a medical professional.

Eptifibatide on Pipelinepharma:

Eptifibatide manufacturers and eptifibatide suppliers can be found on the online Pipelinepharma marketplace, along with a wide array of other drugs which are available for global B2B sale. Currently, at the time of writing, there are 4 trusted manufacturers, suppliers, and distributors situated in countries including India and China. These sellers have been verified according to strict quality control by the Pipelinepharma team, ensuring no time is wasted on the company sourcing process.

Price of eptifibatide and how to buy:

The price of eptifibatide is highly dependent on a variety of factors including location, quantity, and manufacturer. With the cost of wholesale order of intravenous eptifibatide solution in the United Kingdom being approximately $167.03 for 2 mg/mL and $190.99 in the United States, according to bnf.nice.org.uk and drugs.com respectively. Although prices remain confidential on our marketplace, the seller may choose to list the desired price to facilitate transactions. If so, this will be indicated on our online interface with an ‘Accept’ and ‘Negotiate’ button when a price is indicated, and a ‘Get offer’ button being displayed in the absence of a price.